Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06392477
Status:
RECRUITING
Last Update Posted:
2024-06-18
First Post:
2024-04-23
Brief Title:
A Study of DR-0201 in Subjects With RelapsedRefractory B-Cell Non-Hodgkin Lymphoma
Sponsor:
Dren Bio
Organization:
Dren Bio
Study Overview
Official Title:
A Multicenter Multiple Expansion Cohort Phase 1 Study Evaluating the Safety and Activity of DR-0201 as Multiple Ascending Doses in Patients With RelapsedRefractory B Cell Non-Hodgkin Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter multiple expansion cohort Phase 1 study to evaluate the safety tolerability pharmacokinetics pharmacodynamics and anti-tumor activity of DR-0201 in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None